Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.60 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.60 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.60 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29778218 | 1.00 | KCNK3 (1.00) | KCNK3KCNH2KCNA5KCNK5KCNK17 | |
| SCHEMBL12434086 | 0.92 | KCNK3 (0.84) | KCNK3KCNH2KCNA5KCNK5KCNK17 | |
| SCHEMBL12434102 | 0.90 | KCNK3 (0.81) | KCNK3KCNH2KCNA5KCNK5KCNK17 | |
| SCHEMBL12434454 | 0.90 | KCNK3 (0.81) | KCNK3KCNH2KCNA5KCNK5KCNK17 | |
| SCHEMBL726554 | 0.87 | KCNK3 (0.77) | KCNK3KCNH2KCNA5KCNK5KCNK17 | |
| SCHEMBL12434083 | 0.84 | KCNK3 (0.73) | KCNK3KCNH2KCNA5KCNK5KCNK17 | |
| SCHEMBL12434461 | 0.84 | KCNK3 (0.72) | KCNK3KCNH2KCNA5KCNK5KCNK17 | |
| SCHEMBL12434141 | 0.83 | KCNK3 (0.71) | KCNK3KCNH2KCNA5KCNK5KCNK17 | |
| SCHEMBL12434450 | 0.82 | KCNK3 (0.73) | KCNK3KCNH2KCNA5KCNK5KCNK17 | |
| SCHEMBL12434153 | 0.80 | KCNK3 (0.67) | KCNK3KCNH2KCNA5KMT2AKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068591-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-03 | — | — | WO | claimed |
| US-9056833-B2 | Crystalline phases of 2′-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-06-16 | — | — | US | claimed |
| US-20120071520-A1 | CRYSTALLINE PHASES OF 2'--BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8106099-B2 | 2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide or other phenylcarboxamide derivatives with dofetilide, ibutilide, almokalant, sotalol, azimilide, amiodarone, E4031, clofilium, ambasilide, MS551, tedisamil, bertosamil and quinidine as IKr chahel blocker | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-06-11 | — | — | US | claimed |
| EP-2012758-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | Sanofi-Aventis Deutschland GmbH (DE) | 2009-01-14 | — | — | EP | claimed |
| WO-2007124849-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | WO | claimed |
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-22 | — | — | US | claimed |
| WO-2025082731-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025068591-A1 | INTRANASAL FORMULATIONS FOR TREATING OBSTRUCTIVE SLEEP APNEA | MOSANNA THERAPEUTICS AG (CH) | 2025-04-03 | — | — | WO | disclosed |
| EP-2438045-B1 | CRYSTALLINE PHASES OF 2'-{[2-(4-METHOXY-PHENYL)-ACETYLAMINO]-METHYL}-BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-9056833-B2 | Crystalline phases of 2′-{[2-(4-methoxy-phenyl)-acetylamino]-methyl}-biphenyl-2-carboxylic acid (2-pyridin-3-yl-ethyl)-amide | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-06-16 | — | — | US | disclosed |
| US-20120071520-A1 | CRYSTALLINE PHASES OF 2'--BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| US-20120071520-A1 | CRYSTALLINE PHASES OF 2'--BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
| WO-2007124849-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007124849-A2 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-11-08 | — | — | WO | disclosed |
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| WO-2005025674-A1 | COMBINATION OF PHENYLCARBOXAMIDES WITH BETA-ADRENERGIC RECEPTOR BLOCKERS AND USE THEREOF FOR THE TREATMENT OF ATRIAL ARRHYTHMIAS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071520-A1 | CRYSTALLINE PHASES OF 2'--BIPHENYL-2-CARBOXYLIC ACID (2-PYRIDIN-3-YL-ETHYL)-AMIDE | HRH2, CTSH, HRH1 | KCNK3 3825/4885KCNH2 1199/4885KCNA5 3165/4885 |
| US-20090149496-A1 | INHIBITORS OF THE TASK-1 AND TASK-3 ION CHANNEL | KCNN3, CACNA1I, KCNN1 | KCNK3 18/4885KCNH2 80/4885KCNA5 67/4885 |
| US-20070043091-A1 | Kv1.5-BLOCKER FOR THE SELECTIVE INCREASE OF ATRIAL CONTRACTILITY AND TREATMENT OF CARDIAC INSUFFICIENCY | KCNJ2, KCNH2, KCNK5 | KCNK3 31/4885KCNH2 2/4885KCNA5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.